A Randomized, Double-blind, Placebo-controlled, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of AOC 1020 Administered Intravenously to Adult Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)
This research study is investigating a new medication called AOC 1020 for adults aged 18 and over who have Facioscapulohumeral Muscular Dystrophy, or FSHD. This is an early-stage study, meaning it's one of the first times this medicine is being given to people. The main goal is to check how safe it is and if people can handle it well, looking for any side effects. We also want to understand how the body uses and gets rid of the medicine. A smaller part of the study will also look at how it might help with FSHD symptoms. Participants will either receive the new medicine or a harmless saline solution (placebo) through a drip.
Em resumo
Sobre o que é este estudo?
This study is about a new medicine called AOC 1020, designed for people who have a condition called Facioscapulohumeral Muscular Dystrophy, or FSHD for short. FSHD is a genetic condition that causes muscles, especially in the face, shoulders, and arms, to become weak over time. There isn't a cure for FSHD yet, so researchers are always looking for new ways to help.
This is an early-stage study, which in medical terms is called a "Phase 1/2 study." This means it's one of the first times this new medicine will be given to people. The most important thing we want to learn in this study is about safety: are there any side effects, and how well do people tolerate the medicine? We'll also be carefully watching how the body takes in, uses, and gets rid of the medicine, and looking at how much of it reaches the muscles. This information helps us understand if the medicine is working as expected and what the right dose might be.
Participants in this study will either receive the new medicine, AOC 1020, through a drip into their vein, or a placebo. A placebo is a harmless liquid, like salt water, that looks exactly like the real medicine but doesn't contain any active drug. This helps us ensure that any changes we see are truly due to the medicine and not just other factors. By doing this, we hope to find out if AOC 1020 could be a helpful treatment option for people with FSHD in the future.
Pontos principais
- This is an early study for a new FSHD medicine, AOC 1020.
- The main focus is on safety and how the body handles the medicine.
- Participants will receive either the new medicine or a placebo through an IV.
- You must be 18 years or older and have FSHD to be considered.
- Study participation involves multiple clinic visits for assessments.
- Your decision to join is voluntary, and you can withdraw anytime.
Quem pode ser elegível?
This study is open to adult men and women, meaning you need to be at least 18 years old to take part. There isn't an upper age limit mentioned, so older adults could also be considered.
The most important requirement is that you must have a diagnosis of Facioscapulohumeral Muscular Dystrophy (FSHD). The study is specifically for people with this condition.
Beyond these basic requirements, a medical team will review your full health history to make sure the study is a safe and suitable option for you. They will check things like your current medications and other health conditions.
Este estudo pode ser adequado para você?
Responda a estas perguntas rápidas para ver se você pode ser elegível. Este é apenas um guia — a decisão final é da equipe de pesquisa.
- Você tem 18 anos ou mais?
- Have you been diagnosed with Facioscapulohumeral Muscular Dystrophy (FSHD)?
- Você consegue comparecer a consultas regulares na clínica?
- Are you comfortable receiving medication through an intravenous drip?
- Are you willing to potentially receive a placebo instead of the active drug?
O que envolve a participação?
If you decide to take part in this study, you might receive the new medicine (AOC 1020) or a placebo (a harmless saline solution) through a drip into your vein. Neither you nor your study doctor will know whether you are receiving the real medicine or the placebo. You will need to attend several visits to the study clinic over a period of time. These visits will involve various assessments, which could include physical examinations, blood tests, urine tests, questionnaires about your health, and possibly muscle biopsies (taking a tiny sample of muscle) to see how the medicine is affecting your body. The study team will explain everything in detail, including the total duration of your participation and how often you will need to visit the clinic.
Riscos e benefícios potenciais
Localizações (2)
- —Não verificadoPaíses Baixos
- —Não verificadoItália
Perguntas frequentes
O que é FSHD?
FSHD stands for Facioscapulohumeral Muscular Dystrophy. It's a genetic condition that causes muscles, often starting in the face, shoulders, and upper arms, to gradually become weaker.
O que significa 'duplo-cego'?
This means that neither you nor your study doctor will know whether you are receiving the active medicine (AOC 1020) or a placebo (a harmless saline solution). This helps ensure the study results are fair and accurate.
O que é um placebo?
A placebo in this study is a simple salt-water solution that looks exactly like the active medicine but doesn't contain any useful drug. It's used to compare against the real medicine.
Como o medicamento será administrado?
The medicine, or the placebo, will be given through a drip (intravenous infusion) into one of your veins.
Qual é o principal objetivo deste estudo?
The main goal is to see if the new medicine, AOC 1020, is safe and how well people can tolerate it, looking for any side effects. We also want to understand how the body handles the medicine.
Como saber mais
Sempre consulte seu médico ou especialista antes de decidir participar de um estudo.
Interessado em participar?
Discussão
Discussão da comunidade
Desenvolvido pelo nosso fórum em community.patient.info. Por favor, seja respeitoso — isto não é um conselho médico.